NanoLogix, Inc.

72 articles with NanoLogix, Inc.

• NanoLogix Seeks Development & Marketing Partner for Their Sub 1-Hour COVID-19 Detection Tests

  6/3/2020

  NanoLogix, Inc. (OTC: NNLX), an innovator in the rapid detection and identification of viruses and bacteria, is seeking a partner or partners for obtaining FDA Emergency Use Authorization, if required, and for development and marketing of their sub 1-hour COVID-19 Point of Care modified-ELISA detection test. This Rapid Viral Assay can a

• NanoLogix, Inc. Rapid Bacteria Test Unveiled At CAOG, Wins Judges Choice Award; Technology Published In Journal Of Infectious Diseases In Obstetrics And Gynecology

  11/1/2016

• NanoLogix, Inc. Announces Publication Of A Study In Journal Of Microbiology And Experimentation

  1/5/2016

• NanoLogix, Inc. Technology Being Configured For Rapid Ebola Virus Detection

  10/14/2014

• NanoLogix, Inc. Technology Cited In UNITAID Annual Report On TB, Through The World Health Organization

  9/29/2014

• NanoLogix, Inc. To Exhibit At BioOhio Exposition, Receives European Allowance For BNP Patent

  7/8/2014

• NanoLogix, Inc. Welcomes VP For Sales And Marketing

  5/20/2014

• NanoLogix, Inc. Sets New Standard For Extended Shelf Life Of Petri-Plates

  2/24/2014

• NanoLogix, Inc. And Saudi Company To Work Together For Distribution Of NanoLogix Products In The Arabian Gulf Region

  12/4/2013

• EPA and NanoLogix, Inc. to Extend Agreement to 2015

  6/11/2013

• NanoLogix, Inc. to Exhibit at Food Safety Summit in Baltimore and American Society for Microbiology Annual Meeting in Denver

  4/30/2013

• University of Texas Health Science Center at Houston Releases News of Successful NanoLogix, Inc. Test

  3/12/2013

• NanoLogix, Inc. Rapid TB Detection Results Published in Journal of Microbial & Biochemical Technology

  12/17/2012

• NanoLogix, Inc. Rapid Diagnostic Technologies Set to Enter Market Under FDA 510K-Exempt Status

  8/21/2012

• NanoLogix, Inc. Featured in USA Today Group B Streptococcus (GBS) Awareness Campaign

  8/1/2012

• NanoLogix, Inc. Announces Development of Multi-Well, Rapid Diagnostic Test Variant and Exhibits at the American Society for Microbiology General Meeting in San Francisco

  6/13/2012

• NanoLogix, Inc. Provides Testing and Operations Update

  4/24/2012

• NanoLogix, Inc. Provides Testing and Operations Update

  4/24/2012

• NanoLogix, Inc. Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents

  1/10/2012

• NanoLogix, Inc. Technology Delivers Live Tuberculosis (TB) Detection Results in a Revolutionary 4 Days Versus Traditional 21 Days

  11/1/2011